ミズーリ州におけるクローン病の臨床試験
ミズーリ州内の拠点で、クローン病に関する21件の研究が参加者を募集しています。
ミズーリ州内の都市
公式研究テキスト（英語）
Extension Study of Long-term Safety and Efficacy of Tulisokibart in Participants With Crohn's Disease or Ulcerative Colitis (MK-7240-011)
- BVL Research - Kansas ( Site 0292), Liberty
被験者募集中第3相
全年齢 · 全性別 · 2026/10/02更新 · NCT06651281A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
- Mid-America GI Clinical Research ( Site 5130), Kansas City
- BVL Research - Kansas ( Site 5099), Liberty
- Washington University School of Medicine ( Site 5058), St Louis
被験者募集中第3相
16歳〜80歳 · 全性別 · 2026/10/02更新 · NCT06430801Study of Advanced Therapies for the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease or Ulcerative Colitis
- Specialists In Gastroenterology /ID# 283939, St Louis
被験者募集中第2相
18歳〜75歳 · 全性別 · 2026/10/02更新 · NCT07697456A Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in the Community Setting
- SSM Health Medical Group, Bridgeton
- GI Associates Research, LLC, Columbia
- Mid America Gastro Intestinal Consultants, Kansas City
- 他1件
被験者募集中第4相
18歳〜80歳 · 全性別 · 2026/09/30更新 · NCT06581328Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease
- GI Associates Research, LLC /ID# 267433, Columbia
- Bvl Research /ID# 265870, Liberty
- Washington University /ID# 266938, St Louis
被験者募集中第2相
18歳〜75歳 · 全性別 · 2026/09/25更新 · NCT06548542A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease
- BVL Clinical Research, Liberty
被験者募集中第2相
18歳〜75歳 · 全性別 · 2026/09/25更新 · NCT06233461Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
- Washington University School of Medicine, St Louis
被験者募集中第3相
18歳〜70歳 · 全性別 · 2026/09/24更新 · NCT06937099Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
- Siteman Cancer Center at Saint Peters Hospital, City of Saint Peters
- Siteman Cancer Center at West County Hospital, Creve Coeur
- University Health Truman Medical Center, Kansas City
- 他6件
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/23更新 · NCT03816345An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
- BVL Clinical Research-Site Number: 8400005, Liberty
- Washington University School of Medicine-Site Number: 8400075, St Louis
- Gateway Gastroenterology-Site Number: 8400097, St Louis
被験者募集中第3相
16歳〜80歳 · 全性別 · 2026/09/23更新 · NCT07184931A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
- BVL Clinical Research-Site Number: 8400005, Liberty
- Gateway Gastroenterology-Site Number: 8400097, St Louis
被験者募集中第3相
16歳〜80歳 · 全性別 · 2026/09/23更新 · NCT07184944A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease
- SSM Health DePaul Hospital- St. Louis, Bridgeton
被験者募集中第2相
18歳〜85歳 · 全性別 · 2026/09/22更新 · NCT06226883A Master Protocol (IIBD): A Study of Multiple Drugs in Adults With Ulcerative Colitis or Crohn's Disease
- KAD Clinical Research, St Louis
被験者募集中第2相
18歳〜80歳 · 全性別 · 2026/09/22更新 · NCT07483073A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)
- Washington University School of Medicine, St Louis
被験者募集中第3相
2歳〜19歳 · 全性別 · 2026/09/22更新 · NCT04844606A Study of LY4395089 and Mirikizumab (LY3074828) Given Together and Mirikizumab (Alone) in Adults With Crohn's Disease
- KAD Clinical Research, St Louis
被験者募集中第2相
18歳〜80歳 · 全性別 · 2026/09/22更新 · NCT07483099A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease
- Mid-America Gastro-Intestinal Consultants, Kansas City
- BVL Clinical Research, Liberty
- Washington University School of Medicine, St Louis
被験者募集中第4相
18歳〜70歳 · 全性別 · 2026/09/09更新 · NCT06045754DB-3Q for the Treatment of Medically Refractory Crohn's Disease
- Washington University, St. Louis, St Louis
被験者募集中第2相
18歳〜75歳 · 全性別 · 2026/09/01更新 · NCT07625293Moving Beyond Inflammation as a Therapeutic Target for Crohn's Disease
- Washington University School of Medicine, St Louis
被験者募集中第2相
18歳〜80歳 · 全性別 · 2026/06/05更新 · NCT06976853A Study to Investigate Efficacy and Safety of SAR442970 in Patients With Crohn's Disease
- Investigational Site Number: 8400013, St Louis
被験者募集中第2相
18歳〜75歳 · 全性別 · 2026/03/27更新 · NCT06958536A Phase 2 Study to Evaluate Therapies for Inflammatory Bowel Disease
- Mirador Therapeutics Selected Site, Bridgeton
- Mirador Therapeutics Selected Site, Kansas City
- Mirador Therapeutics Selected Site, Liberty
被験者募集中第2相
18歳〜80歳 · 全性別 · 2026/03/12更新 · NCT07113522Treatment of Moderate to Severe Refractory Crohn's Disease
- Washington University in St. Louis, St Louis
被験者募集中第1/2相
18歳〜65歳 · 全性別 · 2025/12/10更新 · NCT06721962Development of a Novel Endoscopic Index and Patient-reported Outcome Measure for Clinical Trials in Participants With Permanent Ileostomy
- Washington University in St Louis School of Medicine, St Louis
被験者募集中観察研究
18歳以上 · 全性別 · 2025/11/12更新 · NCT06670638ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。